Clinical Trial Search

Primary: Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up — 51.8; 49.0 percentage of Participants

Primary: Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population — 48.0; 47.9 percentage of…

Primary: Number of Participants With Confirmed Complete Molecular Response (CMR) — 34 Participants

Primary: Percentage of Leukemic Stem Cells Present in Bone Marrow Aspirate Samples, in This Patient Population — 37.4; 2.32; 0.7; 7.04 percentage of leukemic stem cells

Primary: MMR Rate at 12 Mos. of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who…

Primary: Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Major Cytogenetic Response (MCyR) — 50.8 Percentage of participants

Primary: Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. — 3; 2; 1; 1…

Primary: Number of Participants With Major Cytogenetic Response (MCyR) — 191; 44; 22 Participants

Primary: Response: One Log Decrease in BCR-ABL — 3; 7 Participants

Primary: Number of Patients With Response — 3; 25; 24 Participants

Primary: Participants With Complete Molecular Response (Molecular CR) — 23 Participants

Primary: Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A and B up to 24 Weeks — 23; 26; 1; 3 Participants

Primary: Rate of Confirmed Best Cumulative Complete Molecular Response (CMR) — 13; 6; 91; 97 Participants — p=0.1083

Primary: Progression-free Survival — 2; 0 Participants

Primary: Number of Participants With Molecular Response — 8; 0; 4 Participants

Primary: Number of Participants With Complete Response — 3 Participants

Primary: Number of Participants With Molecular Complete Remission at 3 Month Post Transplant — 3 participants

Primary: Number of Participants With a Major Molecular Response at 12 Months — 103 Participants

Primary: Percentage of Participants With Molecular Response (MR4^0) at 18 Months — 38.3 Percentage of Participants

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months — 74 Participants

Primary: Kaplan-Meier Estimates of Overall Survival (All Randomized Participants) — 98.9; 97.7; 96.0; 93.6 Percentage of participants

Primary: Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population — 67.4; 25.8; 8.7; 41.0 percentage of participants

Primary: Number of Participants With Complete Hematologic Response — 40 participants

Primary: Molecular Response (MR)^4.5 Rate at 48 Weeks and Difference in Rate Between Asciminib + Imatinib and Imatinib Alone — 19.0; 28.6; 0.0 Percentage of participants

Primary: Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical…

Primary: Participants With a Complete Response — 34 Participants

Primary: Major and Overall Hematologic Response (MaHR and OHR) — 2; 34; 36; 4 Participants

Primary: Determine Probability of Long-term Disease Free Survival in JMML — 67 Percentage of participants

Primary: Number of Participants With a Complete Response (CR) — 0; 0; 2; 0 participants